Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Sacubitril/Valsartan vs Entresto in Healthy Thai Subjects
NCT06193187Phase 1Not yet recruiting
- Sponsor
- Dr. Reddy's Laboratories
- Start
- Jan 2024
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sacubitril + valsartan in heart failure (HF) (2 arms), sponsored by Dr. Reddy's Laboratories. Primary endpoints: Peak Plasma Concentration at 48 hours, Area under the plasma concentration versus time curve from time zero to the last measurable concentration at 48 hours and 1 more. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT06193187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193187.